On July 9, 2018, FDA hosted a public meeting on Patient-Focused Drug Development for Chronic Pain. FDA was interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA was particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies. For more information, visit the meeting webpage: [ Ссылка ]
